JW Creagen, Patent for Autoimmune Disease Treatment in China
[Asia Economy Reporter Hyun-ui Cho] JW CreaGen, a subsidiary of JW Pharmaceutical, announced on the 29th that it has completed patent registration with the China National Intellectual Property Administration (SIPO) for the 'Bio-drug Development Technology Using Semi-mature Dendritic Cells.'
This patent relates to a method of producing semi-mature dendritic cells by treating immature dendritic cells with autoantigens and activating substances, and it is a technology for developing treatments and vaccines for autoimmune diseases such as rheumatoid arthritis.
Dendritic cells play a role in either activating or suppressing immune cells depending on their maturation stage. Mature dendritic cells strengthen the weakened immune system of patients and instruct T cells to attack cancer cells, making them useful in the development of anticancer vaccines.
Semi-mature dendritic cells have immune-regulatory functions, controlling excessive immune responses and suppressing immune cells that attack self-tissues, thus they can be utilized in the treatment of immune diseases.
JW CreaGen is currently developing immune disease treatments based on mature dendritic cell-based liver cancer therapeutics (Phase 3 clinical trial), glioblastoma therapeutics (Phase 1/2 clinical trial), and immature dendritic cell production technology.
In May, JW CreaGen received approval for patent registration of this technology from the European Patent Office (EPO) and is currently preparing for final registration in five European countries.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
JW CreaGen CEO Kyung-joon Lee said, “We are gaining recognition for our competitiveness by consecutively securing patents for dendritic cell production technology applicable to autoimmune disease treatment in global markets such as Europe and China,” adding, “We will focus the company’s capabilities on creating added value through successful commercialization and technology transfer.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
